ABSTRACT
Aim: This study analyzes our single-center, retrospective experience on 63 premenopausal breast cancer patients treated with monthly triptorelin and concomitant chemotherapy. Patients & methods: Concomitant chemotherapy and triptorelin were adopted as part of premature ovarian failure prevention strategy. Results: Age at diagnosis was the main factor influencing fertility preservation (p = 0.002). Compared with patients aged 41–45 years, the probability of menses resumption was almost threefold than for women aged 35–40 years, and significantly higher for women aged <35 years (hazard ratio: 9.0; p = 0.0001). The cumulative proportion among patients who resumed menses was 33.3% at 6 months, 75% at 12 months and 87.5% at 24 months. Seven patients attempted pregnancy, and five (71%) obtained healthy deliveries. Conclusion: We observed an acceptable rate of fertility preservation. Age at diagnosis influences fertility preservation.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Editorial assistance was provided by Luca Giacomelli, PhD, on behalf of Content Ed Net; this assistance was funded by Ipsen.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.